BGLAF (BioGaia AB) Owner Earnings per Share (TTM): 0.24 (As of Mar. 2026) — 99% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $12.57
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioGaia AB Owner Earnings per Share (TTM)?

BioGaia AB BGLAF 100 Owner Earnings per Share (TTM) is 0.24 as of Mar. 2026, which is 99% below its 10-year median of 42.06. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 476 Drug Manufacturers companies, BioGaia AB ranks worse than 75.63% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BioGaia AB's Owner Earnings per Share (TTM) ended in Mar. 2026 was $0.24. It's Price-to-Owner-Earnings ratio for today is 50.83.


The historical rank and industry rank for BioGaia AB's Owner Earnings per Share (TTM) or its related term are showing as below:

BGLAF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.75   Med: 42.06   Max: 62.45
Current: 50.79


During the past 13 years, the highest Price-to-Owner-Earnings ratio of BioGaia AB was 62.45. The lowest was 22.75. And the median was 42.06.


BGLAF's Price-to-Owner-Earnings is ranked worse than
75.63% of 476 companies
in the Drug Manufacturers industry
Industry Median: 23.88 vs BGLAF: 50.79

BioGaia AB's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $0.08. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. It's PE Ratio (TTM) ratio for today is 34.96.

BioGaia AB's EPS without NRI for the three months ended in Mar. 2026 was $0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. It's PE Ratio without NRI ratio for today is 34.96.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


BioGaia AB Owner Earnings per Share (TTM) Related Terms


BioGaia AB Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Owner Earnings per Share (TTM) Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.45 0.31 0.23 0.21

BioGaia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.20 0.22 0.21 0.24

BGLAF vs ZTS, UTHR: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Price-to-Owner-Earnings falls into.


BGLAF
100GF Score
BioGaia AB BGLAF
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

BioGaia AB's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 35.4
Depreciation, Depletion and Amortization 2.6
Change In Deferred Tax -10.3
5Y Average of Maintenance Capital Expenditure 1.8
Change In Working Capital 0.7
Shares Outstanding (Diluted Average) 101.2

1. Start with "Net Income" from income statement. BioGaia AB's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was $35.4 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. BioGaia AB's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was $2.6 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. BioGaia AB's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.3 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $1.8 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

BioGaia AB's 5-Year Average Maintenance Capital Expenditure = $1.8 Mil

5. "Change In Working Capital" is from cashflow statement. BioGaia AB's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was $0.7 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. BioGaia AB's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 101.162 Mil.

BioGaia AB's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 35.388 +2.621+-10.331
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1.7681867026669+0.741)/101.162
=0.24

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=12.20/0.24
=50.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.24 mean?
BioGaia AB (BGLAF) has a Owner Earnings per Share (TTM) of 0.24 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on BioGaia AB. This is 99% below median its historical median of 42.06. Over the past decade, BioGaia AB's Owner Earnings per Share (TTM) has ranged from 22.75 to 62.45. According to the industry distribution chart, BioGaia AB ranks #360 out of 476 companies in the Drug Manufacturers industry, placing it in the top 75.6%.
Is BioGaia AB's Owner Earnings per Share (TTM) too high?
BioGaia AB's current Owner Earnings per Share (TTM) of 0.24 is 99% below median its 10-year median of 42.06. Over the past 10 years, this metric has ranged from a low of 22.75 to a high of 62.45. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.88. BioGaia AB's value of 0.24 is 99% below this industry median. Based on the distribution chart, BioGaia AB ranks #360 out of 476 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #360 out of 476 companies for Owner Earnings per Share (TTM). This places BioGaia AB in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.88. BioGaia AB's value of 0.24 is 99% below this benchmark. Historically, BioGaia AB's own Owner Earnings per Share (TTM) has ranged from 22.75 to 62.45 over the past decade. While the company's 10-year median is 42.06 vs. the industry median of 23.88, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.88, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Owner Earnings per Share (TTM) of 0.24 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on BioGaia AB. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Owner Earnings per Share (TTM) is 0.24, which is 99% below median its own 10-year median of 42.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.57, compared to a current price of $12.20 — trading 2.9% below its estimated fair value. The current Owner Earnings per Share (TTM) is 0.24, which is 99% below median its 10-year median of 42.06 and 99% below the Drug Manufacturers industry median of 23.88. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Owner Earnings per Share (TTM) is 0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 2.9% below its estimated GF Value™ of $12.57. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BGLAF:

  • Owner Earnings per Share (TTM): 0.24 (99% below median its 10-year median of 42.06)
  • GF Value™: $12.57 vs. price of $12.20 (2.9% below fair value)
  • GF Score™: 100/100 with 5 warning signs
  • Industry Position: 99% below the Drug Manufacturers median (#360 of 476)

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$12.57
GF Value